Injectable Packaging Report 2026-2032: 82.7B Units, Drug Stability & Weigao Group
公開 2026/04/07 18:42
最終更新
-
Global Leading Market Research Publisher QYResearch announces the release of its latest report *"Injection Container Components - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032"*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Injection Container Components market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Injection Container Components was estimated to be worth US$ 6215 million in 2025 and is projected to reach US$ 8824 million, growing at a CAGR of 5.2% from 2026 to 2032. Injection container components are functional primary packaging parts used for injectable formulations, including Caps, Injection Stoppers, Ports, and Others. These components ensure the sterility, safety, and stability of the drug solution while enhancing convenience for drug preparation, administration, and clinical use. With the growth of the injectable market and increasing demand for intravenous therapies, the technical requirements for these components—such as packaging safety, sealing performance, self-sealing after puncture, and container compatibility—continue to rise. In 2024, the global average price of injection container components was approximately USD 0.072 per unit, with an annual sales volume of around 82.7 billion units.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6096928/injection-container-components
1. Core Components: Caps, Injection Stoppers & Ports
The injection container components market is built upon three primary component types: caps (aluminum or plastic, tamper-evident), injection stoppers (rubber or elastomeric, self-sealing), and ports (PP or polycarbonate, for IV bags). Unlike standard packaging closures, injection components must maintain sterility, provide hermetic sealing, and withstand multiple punctures (10-20 times for stoppers, 5-15 times for ports). Since Q4 2025, new coated stoppers (fluoropolymer barrier) have reduced drug adsorption by 80% for sensitive biologics (monoclonal antibodies, insulin).
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals steady growth across component types and applications:
By Type:
Injection Stoppers (rubber, elastomeric) holds approximately 45% of market revenue, largest segment for vials and cartridges (drug reconstitution, multi-dose).
Ports (PP, polycarbonate) accounts for 30%, used for IV bags (saline, TPN, blood products).
Caps (aluminum, plastic) holds 20%.
Others (seals, adapters) represents 5%.
By Application:
Intravenous Fluids (saline, glucose, Ringer's lactate) leads with 55% of revenue, largest volume (hospital IV therapy).
Nutrients (total parenteral nutrition, TPN) accounts for 20%, fastest-growing at 7% CAGR.
Blood Products (blood, plasma, albumin) holds 15%.
Other (chemotherapy, vaccines, insulin) represents 10%.
Geographic Note: Asia-Pacific leads with 55% of volume (China 35%, India 10%), followed by North America (20%) and Europe (15%). China dominates component production; North America/Europe focus on high-value coated stoppers and specialty ports.
The Injection Container Components market is segmented as below:
By Company: Sealed Air, RENOLIT, Polycine, Mediparmaplan, Shikoku Kakoh, SR TechnoPack, Baxter, Prasad Meditech, Jiangsu Best New Medical Materials, Shandong Ujoin Medical Technology, Hubei Huaqiang High-Tech, Jumin Biotechnology, Nanjing Otsuka Techbond Techno, Weigao Group, Shanghai Shengben Packaging Materials, Huaren Pharmaceutical, Huafeng Packaging, Yantai Huazheng Medical Apparatus Technology, Hebei Xiangyi, Qingdao Haoen Pharmaceutical Consumables, Hunan Yike Pharmaceutical Packaging Materials, Yangzhong Hongyun Pharmaceutical Packaging, Chongqing Qianlong Pharmaceutical Packaging, Jiangsu Jinyangzi Packaging Technology, Hai'an County Jianmin Rubber & Plastic, Jinan Jinhengyu Packaging, Suzhou Chuangyang New Materials Technology, Jiangsu Changjiang Lids, Shandong Guohui New Materials
Segment by Type: Caps, Injection Stoppers, Ports, Others
Segment by Application: Intravenous Fluids, Blood Products, Nutrients, Other
3. Technical Deep Dive: Self-Sealing, Sterilization & Extractables/Leachables
A persistent technical challenge across all injection container components is self-sealing after puncture (stopper and port integrity after needle withdrawal), sterilization compatibility (autoclave, gamma, ETO), and extractables/leachables (E&L) (chemical migration into drug solution).
Recent innovations addressing these issues include:
Fluoropolymer-coated stoppers (Sealed Air, Jiangsu Best) reducing drug adsorption (insulin, monoclonal antibodies) by 80%, and minimizing leachables (2-mercaptobenzothiazole) by 90%.
Self-sealing silicone valves (RENOLIT, Yangzhong Hongyun) for IV bag ports, resealing after 10-20 punctures (19-22G needles), reducing leak rate by 90% vs non-valved ports.
Autoclavable PP ports (Prasad Meditech, Shandong Ujoin) withstanding 121°C steam sterilization without deformation, maintaining seal integrity.
ISO 8871-compliant rubber stoppers (Shikoku Kakoh, SR TechnoPack) with validated E&L profiles (USP <381>, ISO 10993), required for FDA/EMA submissions.
Exclusive observation: Unlike oral or topical packaging, injection container components are sterile and parenteral—direct contact with drug solution that enters bloodstream. Key requirements: (1) self-sealing after needle puncture (stopper must reseal to prevent contamination), (2) low extractables (no leachables into drug), (3) sterilization compatibility (terminal sterilization without degradation). For rubber stoppers (vials, cartridges), butyl rubber is standard (low permeability, good self-sealing), but extractables (2-mercaptobenzothiazole, zinc) remain concerns. Coated stoppers (fluoropolymer, plasma-coated) reduce drug adsorption and leachables, critical for biologics (monoclonal antibodies at $5,000-10,000 per vial). For IV bag ports, self-sealing silicone valves allow multiple drug admixtures (antibiotics, electrolytes) without leakage. Cost: standard stopper $0.02-0.05, coated stopper $0.10-0.25. For a large pharma (1B vials annually), coated stoppers cost $100-250M vs $20-50M for standard, but prevent drug loss ($5,000-10,000 per vial). The trend is toward elastomeric closures with integrated safety features (Sealed Air's "SmartStopper" with RFID for anti-counterfeiting).
4. Industry Stratification: Vial Stoppers vs. IV Ports vs. Cartridge Plungers
For injectable manufacturers, component requirements differ significantly by container type:
Dimension Vial Stoppers IV Bag Ports Cartridge Plungers
Primary material Butyl rubber (coated) PP, silicone valve Bromobutyl rubber
Key function Self-sealing (10-20 punctures) Drug admixture (5-15 punctures) Syringeability (smooth plunger movement)
Sterilization Autoclave, gamma Autoclave Autoclave, gamma
Key requirement Low extractables, drug compatibility Leak resistance, valve integrity Break-loose force (5-15 N), glide force
Price per unit $0.03-0.15 $0.08-0.20 $0.05-0.15
Key suppliers Sealed Air, Shikoku Kakoh, SR TechnoPack RENOLIT, Yangzhong Hongyun, Yantai Huazheng Weigao Group, Jiangsu Best, Baxter
Vial stoppers prioritize self-sealing and low extractables. IV ports prioritize leak resistance and multiple punctures. Cartridge plungers require consistent break-loose and glide forces (ISO 11040).
5. User Case & Policy Update
Case Study – Pfizer (Global, Biologics Vials):
Pfizer uses Sealed Air fluoropolymer-coated stoppers for monoclonal antibody vials (Xeljanz, Enbrel). Results: 80% reduction in drug adsorption, 90% reduction in leachables, 500M+ stoppers annually.
Case Study – Baxter (Global, IV Bags):
Baxter uses RENOLIT double-valve ports for drug admixture bags. Results: Self-sealing silicone valve (20 punctures), 99.99% leak-free, 2B+ ports annually.
Case Study – Weigao Group (China, Cartridge Plungers):
Weigao Group produces 5B+ cartridge plungers annually for insulin pens (Novo Nordisk, Sanofi). Results: Break-loose force 8-12 N, glide force 5-8 N, ISO 11040 compliant, 50% lower cost vs European suppliers.
Policy Update (June 2026):
USP <381> (elastomeric closures, 2025 update) requires extractables/leachables (E&L) testing for rubber stoppers (GC-MS, LC-MS), with limits for 2-MBT (<0.1 μg/mL).
FDA Guidance (2025) on "Container Closure Systems for Injectable Products" requires coated stopper validation (drug adsorption, leachables) for biologics.
EU MDR 2017/745 (Medical Device Regulation) classifies syringe plungers as Class IIa medical devices, requiring clinical evaluation and CE marking.
China's NMPA (2026) issued "Guidelines for Injection Container Components" aligning with USP <381> and ISO 8871, requiring E&L testing for rubber stoppers.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
The global market for Injection Container Components was estimated to be worth US$ 6215 million in 2025 and is projected to reach US$ 8824 million, growing at a CAGR of 5.2% from 2026 to 2032. Injection container components are functional primary packaging parts used for injectable formulations, including Caps, Injection Stoppers, Ports, and Others. These components ensure the sterility, safety, and stability of the drug solution while enhancing convenience for drug preparation, administration, and clinical use. With the growth of the injectable market and increasing demand for intravenous therapies, the technical requirements for these components—such as packaging safety, sealing performance, self-sealing after puncture, and container compatibility—continue to rise. In 2024, the global average price of injection container components was approximately USD 0.072 per unit, with an annual sales volume of around 82.7 billion units.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6096928/injection-container-components
1. Core Components: Caps, Injection Stoppers & Ports
The injection container components market is built upon three primary component types: caps (aluminum or plastic, tamper-evident), injection stoppers (rubber or elastomeric, self-sealing), and ports (PP or polycarbonate, for IV bags). Unlike standard packaging closures, injection components must maintain sterility, provide hermetic sealing, and withstand multiple punctures (10-20 times for stoppers, 5-15 times for ports). Since Q4 2025, new coated stoppers (fluoropolymer barrier) have reduced drug adsorption by 80% for sensitive biologics (monoclonal antibodies, insulin).
2. Market Data & Segment Performance (Last 6 Months)
Recent industry data (January–June 2026) reveals steady growth across component types and applications:
By Type:
Injection Stoppers (rubber, elastomeric) holds approximately 45% of market revenue, largest segment for vials and cartridges (drug reconstitution, multi-dose).
Ports (PP, polycarbonate) accounts for 30%, used for IV bags (saline, TPN, blood products).
Caps (aluminum, plastic) holds 20%.
Others (seals, adapters) represents 5%.
By Application:
Intravenous Fluids (saline, glucose, Ringer's lactate) leads with 55% of revenue, largest volume (hospital IV therapy).
Nutrients (total parenteral nutrition, TPN) accounts for 20%, fastest-growing at 7% CAGR.
Blood Products (blood, plasma, albumin) holds 15%.
Other (chemotherapy, vaccines, insulin) represents 10%.
Geographic Note: Asia-Pacific leads with 55% of volume (China 35%, India 10%), followed by North America (20%) and Europe (15%). China dominates component production; North America/Europe focus on high-value coated stoppers and specialty ports.
The Injection Container Components market is segmented as below:
By Company: Sealed Air, RENOLIT, Polycine, Mediparmaplan, Shikoku Kakoh, SR TechnoPack, Baxter, Prasad Meditech, Jiangsu Best New Medical Materials, Shandong Ujoin Medical Technology, Hubei Huaqiang High-Tech, Jumin Biotechnology, Nanjing Otsuka Techbond Techno, Weigao Group, Shanghai Shengben Packaging Materials, Huaren Pharmaceutical, Huafeng Packaging, Yantai Huazheng Medical Apparatus Technology, Hebei Xiangyi, Qingdao Haoen Pharmaceutical Consumables, Hunan Yike Pharmaceutical Packaging Materials, Yangzhong Hongyun Pharmaceutical Packaging, Chongqing Qianlong Pharmaceutical Packaging, Jiangsu Jinyangzi Packaging Technology, Hai'an County Jianmin Rubber & Plastic, Jinan Jinhengyu Packaging, Suzhou Chuangyang New Materials Technology, Jiangsu Changjiang Lids, Shandong Guohui New Materials
Segment by Type: Caps, Injection Stoppers, Ports, Others
Segment by Application: Intravenous Fluids, Blood Products, Nutrients, Other
3. Technical Deep Dive: Self-Sealing, Sterilization & Extractables/Leachables
A persistent technical challenge across all injection container components is self-sealing after puncture (stopper and port integrity after needle withdrawal), sterilization compatibility (autoclave, gamma, ETO), and extractables/leachables (E&L) (chemical migration into drug solution).
Recent innovations addressing these issues include:
Fluoropolymer-coated stoppers (Sealed Air, Jiangsu Best) reducing drug adsorption (insulin, monoclonal antibodies) by 80%, and minimizing leachables (2-mercaptobenzothiazole) by 90%.
Self-sealing silicone valves (RENOLIT, Yangzhong Hongyun) for IV bag ports, resealing after 10-20 punctures (19-22G needles), reducing leak rate by 90% vs non-valved ports.
Autoclavable PP ports (Prasad Meditech, Shandong Ujoin) withstanding 121°C steam sterilization without deformation, maintaining seal integrity.
ISO 8871-compliant rubber stoppers (Shikoku Kakoh, SR TechnoPack) with validated E&L profiles (USP <381>, ISO 10993), required for FDA/EMA submissions.
Exclusive observation: Unlike oral or topical packaging, injection container components are sterile and parenteral—direct contact with drug solution that enters bloodstream. Key requirements: (1) self-sealing after needle puncture (stopper must reseal to prevent contamination), (2) low extractables (no leachables into drug), (3) sterilization compatibility (terminal sterilization without degradation). For rubber stoppers (vials, cartridges), butyl rubber is standard (low permeability, good self-sealing), but extractables (2-mercaptobenzothiazole, zinc) remain concerns. Coated stoppers (fluoropolymer, plasma-coated) reduce drug adsorption and leachables, critical for biologics (monoclonal antibodies at $5,000-10,000 per vial). For IV bag ports, self-sealing silicone valves allow multiple drug admixtures (antibiotics, electrolytes) without leakage. Cost: standard stopper $0.02-0.05, coated stopper $0.10-0.25. For a large pharma (1B vials annually), coated stoppers cost $100-250M vs $20-50M for standard, but prevent drug loss ($5,000-10,000 per vial). The trend is toward elastomeric closures with integrated safety features (Sealed Air's "SmartStopper" with RFID for anti-counterfeiting).
4. Industry Stratification: Vial Stoppers vs. IV Ports vs. Cartridge Plungers
For injectable manufacturers, component requirements differ significantly by container type:
Dimension Vial Stoppers IV Bag Ports Cartridge Plungers
Primary material Butyl rubber (coated) PP, silicone valve Bromobutyl rubber
Key function Self-sealing (10-20 punctures) Drug admixture (5-15 punctures) Syringeability (smooth plunger movement)
Sterilization Autoclave, gamma Autoclave Autoclave, gamma
Key requirement Low extractables, drug compatibility Leak resistance, valve integrity Break-loose force (5-15 N), glide force
Price per unit $0.03-0.15 $0.08-0.20 $0.05-0.15
Key suppliers Sealed Air, Shikoku Kakoh, SR TechnoPack RENOLIT, Yangzhong Hongyun, Yantai Huazheng Weigao Group, Jiangsu Best, Baxter
Vial stoppers prioritize self-sealing and low extractables. IV ports prioritize leak resistance and multiple punctures. Cartridge plungers require consistent break-loose and glide forces (ISO 11040).
5. User Case & Policy Update
Case Study – Pfizer (Global, Biologics Vials):
Pfizer uses Sealed Air fluoropolymer-coated stoppers for monoclonal antibody vials (Xeljanz, Enbrel). Results: 80% reduction in drug adsorption, 90% reduction in leachables, 500M+ stoppers annually.
Case Study – Baxter (Global, IV Bags):
Baxter uses RENOLIT double-valve ports for drug admixture bags. Results: Self-sealing silicone valve (20 punctures), 99.99% leak-free, 2B+ ports annually.
Case Study – Weigao Group (China, Cartridge Plungers):
Weigao Group produces 5B+ cartridge plungers annually for insulin pens (Novo Nordisk, Sanofi). Results: Break-loose force 8-12 N, glide force 5-8 N, ISO 11040 compliant, 50% lower cost vs European suppliers.
Policy Update (June 2026):
USP <381> (elastomeric closures, 2025 update) requires extractables/leachables (E&L) testing for rubber stoppers (GC-MS, LC-MS), with limits for 2-MBT (<0.1 μg/mL).
FDA Guidance (2025) on "Container Closure Systems for Injectable Products" requires coated stopper validation (drug adsorption, leachables) for biologics.
EU MDR 2017/745 (Medical Device Regulation) classifies syringe plungers as Class IIa medical devices, requiring clinical evaluation and CE marking.
China's NMPA (2026) issued "Guidelines for Injection Container Components" aligning with USP <381> and ISO 8871, requiring E&L testing for rubber stoppers.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 18 years of experience and a dedi…
最近の記事
タグ